-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $80

Benzinga·01/07/2026 13:05:19
语音播报
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $60 to $80.